Parexel quickens the PACE with new hires
This article was originally published in Scrip
The CRO Parexel International has appointed several executives to its global team of late phase and observational research experts in its PACE (Peri-Approval Clinical Excellence) group. This team now consists of Peggy Schrammel, vice-president and global head portfolio management, Neal Mantick, senior director, global observational research, Dr David Brown, vice-president, epidaemiology, and Dr Deborah Lubeck, vice-president, health economics and outcomes research.
You may also be interested in...
Perhaps only a man who inherited an enthusiasm for peptides could, without a trace of irony, cast diabetes drug development as the work of a pastry chef. But for David Solomon, the son of a peptide devotee, mixed metaphors and stretched comparisons are simply the spray thrown up by his unbridled enthusiasm for his chosen trade, that of basketball coach to GLP-1 receptor agonist developer Zealand Pharma.
"How the hell will Glaxo need you? You've only got a few people, they've got about 50,000!"